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SUMMARY
The supramolecular iron cylinder, [Fe2L3]Cl4 (L =
C25H20N4), shows unprecedented DNA binding
in vitro, inducing intramolecular DNA coiling and
also targeting Y-shaped DNA junctions. We investi-
gated its effects on proliferation and survival in both
tumor and normal cell lines. Iron cylinder reduced
mitochondrial activity of cultureswith potency similar
to cisplatin, inhibited the cell cycle, and increasedcell
death by apoptosis. Associated with this, we
observed a lowering of the association of propidium
iodide with cellular DNA consistent with an observed
competitive displacement of PI from naked DNA by
cylinders. Importantly, and in contrast to existing
anticancer drugs such as cisplatin, the iron cylinder
[Fe2L3]
4+ was not genotoxic. In summary, the design
of metal complexes such as [Fe2L3]
4+ with potential
anticancer properties in the absence of genotoxicity
may represent a significant step toward therapeutic
advancement.
INTRODUCTION
Agents that bind to DNA have the potential to control gene
expression in cells and organisms (Dervan, 2001; Nielsen,
2001; Thuong and Helene, 1993; Da Ros et al., 2005; Hannon,
2007a). Potential applications include the ability to regulate
a specific gene through binding of an agent with exclusive
sequence or structure specificity. Less specific binding can
also find application, and indeed a number of DNA binding
agents of low specificity are in widespread clinical use for treat-
ing cancers and viral diseases. Such drugs are commonly small
synthetic molecules and include intercalators such as the an-
thracycline antibiotics (for example adriamycin) used to treat
cancers (Martı´nez and Chaco´n-Garcı´a, 2005), minor-groove
binders such as the synthetic diarylamidines berenil and pent-
amidine which are used to treat sleeping sickness (Baraldi
et al., 2004), and the anticancer metallo drug cisplatin which
acts via coordinative binding to two neighboring guanine bases
of DNA, resulting in kinks in the DNA (Takahara et al., 1995;
Reedijk, 1996; Lippert, 1999; Guo and Sadler, 2000; Hannon,
2007b).
We have pioneered the use of supramolecular chemistry to
design synthetic agents which are of similar size and shape to
the protein motifs used in nature to recognize DNA (Hannon
et al., 2001a; Meistermann et al., 2002). In particular, we have
designedmetallo-supramolecular cylinders which are of a similar
size (approximately 2 nm in length and 1 nm in diameter) and
shape to the zinc finger motifs found in certain DNA-recognition
proteins. These synthetic supramolecular cylinders bear a tetra-
cationic charge and are composed of three ligand strands
wrapped about two metal ions to give an [M2L3]
4+ formulation
(Hannon et al., 2001a, 2001b; Meistermann et al., 2002; Ker-
ckhoffs et al., 2007). The cylinders are the correct size and shape
to fit into the B-DNA major groove spanning across about five
base pairs, but are too large to bind in the minor groove (Hannon
et al., 2001a; Meistermann et al., 2002; Moldrheim et al., 2002;
Khalid et al., 2006). Although the cylinders may be designed
with a variety of different metal ions, the main focus of our
DNA binding studies has been the di-iron (II) cylinder [Fe2L3]
4+,
[Fe2(C25H20N4)3]Cl4 (Figure 1), which has a deep purple color
which provides a useful spectroscopic handle to follow its
binding. This synthetic tetracationic supramolecular cylinder
binds strongly (binding constant >107 M1) and noncovalently
to the major groove of DNA and induces dramatic and unex-
pected intramolecular DNA coiling that is unprecedented with
synthetic agents and somewhat reminiscent of the effect of
histones (Hannon et al., 2001a; Meistermann et al., 2002).
Although that coiling appears to be a consequence of major-
groove binding, very recently it has been established by X-ray
crystallography and NMR that this agent can also bind to DNA
in a second mode: at the heart of a Y-shaped DNA three-way
junction (Oleksi et al., 2006; Cerasino et al., 2007; Malina et al.,
2007). Such a mode of DNA recognition is without precedent.
Given the remarkable and unprecedented DNA binding proper-
ties of the cylinder, we were intrigued to explore the effect of
these supramolecular cylinders on biological cells.
It is particularly instructive to consider this compound in the
light of the cisplatin [PtCl2(NH3)2] family of drugs (cisplatin, carbo-
platin, nedaplatin, and oxaliplatin), which are among the leading
anticancer drugs in the clinic and are the archetypal metal-based
drugs (Takahara et al., 1995; Reedijk, 1996; Lippert, 1999; Guo
and Sadler, 2000; Hannon, 2007b). These platinum drugs are1258 Chemistry & Biology 15, 1258–1267, December 22, 2008 ª2008 Elsevier Ltd All rights reserved
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to the N7 positions of DNA purine bases. Ultimately, this leads
to DNA damage, mutations, and lesions that cannot be repaired.
In contrast, the supramolecular cylinders are not onlymuch larger
in size but also lack the presence of available coordination sites
on the metals. They are thus unable to bind by formation of
metal-nitrogen bonds to the DNA and instead bind through non-
covalent interactions. Therefore, we anticipated that this supra-
molecular iron cylinder, [Fe2L3]
4+, might have quite different
biological effects from those of the platinum drugs.
In the current study, we demonstrate that the supramolecular
cylinder [Fe2L3]Cl4 (L = C25H20N4) is a potent inhibitor of cellular
proliferation in a panel of tumor cells and induces cytostasis and
apoptosis in the myeloid leukemia cell line HL-60. Crucially, we
report no evidence that the cylinder [Fe2(C25H20N4)3]Cl4 is geno-
toxic as assessed by either the Ames test or the Comet assay,
indicating a nongenotoxic mechanism of action.
RESULTS
Design and Synthesis of the Iron Cylinder [Fe2L3]
4+
The iron(II) cylinder [Fe2L3]
4+ is prepared in high yield by warming
the ligand and iron(II) chloride in a 3:2 ratio in methanol solution
for a few hours. The design of organic ligand L is such that two
bidentate metal binding sites are separated by a 1,4-diphenyl-
methane spacer. The spacer prevents the two metal binding
sites from binding to the same metal, and a dinuclear complex
results. With a metal ion such as iron(II) which prefers a six-coor-
dinate octahedral coordination geometry, three such binding
sites are required to complete the coordination sphere of the
metal. The programmed outcome is a dimetallic structure with
three organic ligand strands wrapping around the dimetallo
core. The cylinder bears a tetracationic charge (arising from
the two iron[+2] centers) and can be isolated with a variety of
counterions, with the choice of counterion influencing the
solubility. The hexafluorophosphate salt affords good solubility
in organic solvents (but not aqueous or alcoholic solvents),
whereas the chloride salt has good water solubility and is used
for the biological studies herein. The electrospray mass spectra
of the salts confirm the expected 2:3 M:L stoichiometry with
peaks corresponding to {Fe2L3}
4+ and {Fe2L3X}
3+ (X = PF6, Cl).
The iron(II) centers are low spin and the salts are consequently
diamagnetic and are deep purple in color due to intense metal
to ligand charge transfer transitions in the visible region. The
NMR spectra confirm the presence of a single solution species
of high symmetry. An X-ray crystal structure of the hexafluoro-
phosphate salt of this iron cylinder confirms the triple-stranded
helical nature of the cation (Kerckhoffs et al., 2007; ccdb
622770). The formation of such triple-stranded metallo-supra-
molecular structures (termed triple-helicates) is well established
(Childs andHannon, 2004), although the iron cylinder differs from
many such arrays in the rigidity of its cylindrical structure. Along-
side the metal-ligand interactions holding the three strands
together, the aryl rings at the center of the cylinder form face-
edge p-stacking interactions with each other in two groups of
three, such that within a group of three each ring presents
a face to a ring on one neighboring strand and an edge to
a ring on the other neighboring strand. The consequences of
this are two-fold. (1) The cylinder structure is supported by inter-
actions along its length giving rise to a relatively rigid structure
(this contrasts with other triple-helicates, where binding sites
are more usually linked by flexible and floppy alkyl chains;
Kramer et al., 1993). (2) The aryl rings are oriented about the
metal-metal axis (rather than perpendicular to it as in Charbon-
niere et al., 1998), giving rise to the cylindrical or barrel-shaped
structure. The structure of the iron(II) cylinder [Fe2L3]
4+ is not
only distinct from other helicates but quite different in size and
shape from other multimetallic DNA binders such as diruthenium
bis-intercalators which contain two bulky metal centers linked
through just one strand (directly or via a floppy spacer; Lincoln
and Norde´n, 1998; O¨nfelt et al., 2002) and the polynuclear
Figure 1. Molecular Structure of the Supramolecular Iron Cylinder
Tetracation
[Fe2L3]
4+ hydrogens and chloride counter ions are omitted for the sake of
clarity (structural data; Kerckhoffs et al., 2007; Cambridge Crystallographic
Database 622770).Chemistry & Biology 15, 1258–1267, December 22, 2008 ª2008 Elsevier Ltd All rights reserved 1259
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alkyl chains (Komeda et al., 2006). It is the size and shape of the
iron cylinders (both of which are inherent consequences of their
supramolecular architecture) that give rise to their dramatic and
unprecedented DNA binding properties as illustrated by the
crystal structure of an iron cylinder in complex with a DNA
three-way junction in which the cylinder fits perfectly into the
heart of the DNA junction without significant structural perturba-
tion (Oleksi et al., 2006).
Relative Effects of Iron Cylinder [Fe2L3]
4+
on Mitochondrial MTT Reduction
The iron cylinder [Fe2L3]
4+ inhibited 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) mitochondrial activity at
low micromolar concentrations in the nontumor MRC5 and
tumor HBL100, SKOV3, T47D, and HL-60 cell lines shown in
comparison to cisplatin (Table 1). This inhibition may indicate a
direct toxicity to cellular mitochondria but can also be indicative
of reduced cell number by cell death or by inhibition of growth
(see below).
No Evidence for Cylinder-Related Genotoxicity
When tested up to concentrations cytotoxic to bacteria, the iron
cylinder [Fe2L3]
4+ was negative in the Ames bacterial mutage-
nicity test either with or without metabolic activation by S9 using
either TA98 or TA100 strains of Salmonella typhimurium. These
strains are used todetect frameshift andpointmutations, respec-
tively (Maron and Ames, 1983). The iron cylinder [Fe2L3]
4+ was
tested at 8, 16, and 32 mM (higher concentrations were toxic to
the bacteria) and the maximum number of bacterial revertants
observed were 16 ± 6 (no S9) and 18 ± 3 (+S9) compared to
13±4 (noS9) and18±4 (+S9) for controls in theTA98strain. Simi-
larly, values of 137 ± 14 (no S9) and 146 ± 17 (+S9) compared to
123 ± 3 (no S9) and 135 ± 9 (+S9) for controls in the TA100 strain
also indicated a lackofmutagenicity of the iron cylinder. To inves-
tigate possible cylinder-related genotoxicity in mammalian cell
lines, we investigated whether iron cylinder treatment could
cause DNA strand breaks utilizing the Comet assay. There was
no evidence that the iron cylinder treatment (0–25 mM, 24 hr)
causes DNA strand breaks in HBL100, MRC5, or HL-60 cell lines
under these experimental conditions (Table 2). In addition, there
was also no evidence for DNA strand breaks in the SKOV3 cell
line (data not shown).
Iron Cylinder Inhibits Cellular Proliferation
and Causes Apoptosis
Treatment of cultures with iron cylinder [Fe2L3]
4+ resulted in inhi-
bition of cell growth, and concentrations as low as 7 mM almost
completely arrested growth of cultures in all the cell lines inves-
tigated (HBL100, SKOV3, and MRC5). This potent cytostasis is
shown in Figure 2. For comparison, cisplatin inhibited cellular
proliferation at concentrations of 2.5–5 mM in the same cell lines
(data not shown). To investigate the possible mechanism of
growth inhibition, we investigated whether treatment with iron
cylinder could alter the distribution of cells within the cell cycle.
For technical reasons, we chose to use the leukemic cell line
HL-60 which grows in suspension and is therefore more
amenable to cell-cycle analysis. Concentrations of 10, 25, and
100 mM were tested over several time periods (24 and 48 hr).
The 100 mM dose was directly cytotoxic and only necrotic cells
were obtained (data not shown). At 24 hr in 10 mM treated cells,
we observed an increased percentage of cells in G1/G0 from
40.0% ± 3.5% in controls to 64.7% ± 4.5% in treated cultures
together with a reduction in the percentage of cells in S phase
(22.8% ± 6% compared to 43.8% ± 7%) (n = 4 experiments;
Figure 3A). The differences between control and treated cells
were highly statistically significant (p < 0.001, t test). An accumu-
lation in G0/G1 was not observed in cells treated with 25 mM iron
cylinder [Fe2L3]
4+, although the reduction in S phase was
maintained. In addition, the higher dose of 25 mM gave rise to
the accumulation of significant numbers of sub-G1 events (Fig-
ure 3B), which is indicative of cells undergoing programmed
cell death, apoptosis (Heffeter et al., 2006). To further investigate
this, we used dual propidium iodide (PI) and annexin-V (AV) stain-
ing. AV binds to the surface of apoptotic cells. Cells initiating
apoptosis but that remain viable exclude PI. Thus, cells that
are AV+ve;PIve represent early apoptotic cells and double posi-
tives represent postapoptotic cells. Treatment with 25 mM iron
cylinder [Fe2L3]
4+ resulted in a time-dependent accumulation
of AV-positive cells. At 48 hr, 17.1% of cells were AV positive,
which is in close agreement with the 23.4% sub-G1 events iden-
tified by cell-cycle analysis. The flow cytometry analyses of
HL-60 apoptosis data were complemented by data obtained
using adherent cell lines in the DNA diffusion assay (which
measures DNA fragmentation as a critical stage of apoptosis),
Using this assay, there was no evidence for apoptosis following
treatment with cylinder for 24 hr (0–25 mM). However, following
treatment for 48 and 72 hr, we observed a concentration-depen-
dent increase in the percentage of apoptotic nuclei which was
statistically significant at the 25 mM dose (Figure 4).
Of particular interest, associated with the cell-cycle arrest and
induction of apoptosis, we observed a lowering of the intensity
of the PI signal, indicating a reduced association with cellular
Table 1. IC50 Concentrations (mM) of Iron Cylinder [Fe2L3]Cl4 and
Cisplatin in a Panel of Cell Lines as Assessed by the MTT Assay
HBL100 T47D SKOV3 HL-60 MRC5
Iron cylinder 27 ± 5 52 ± 10 35 ± 5 18 ± 3 19 ± 3
Cisplatin 4.9 ± 0.3 28 ± 1.7 6 ± 0.3 7 ± 1 <3
See Experimental Procedures. Cells were treated for 72 hr with iron
cylinder (0–129 mM) or cisplatin (0–100 mM). The results represent the
mean of three separate experiments ± SD (n = 3).
Table 2. Lack of Induction of DNA Strand Breaks following
Cylinder Treatment as Assessed by the Alkaline Comet Assay
Iron Cylinder (mM) MRC5 HBL100 HL-60
0 1.43 ± 0.82 4.89 ± 3.84 0.27 ± 0.15
5 2.18 ± 0.12 8.93 ± 4.07 0.40 ± 0.51
10 2.54 ± 0.47 6.16 ± 4.41 0.39 ± 0.47
15 2.31 ± 0.57 6.29 ± 4.17 0.45 ± 0.39
20 1.86 ± 0.44 6.48 ± 2.46 1.95 ± 2.33
25 2.32 ± 0.22 ND ND
The results represent tail DNA% ±SD (n = 3) of three independent exper-
iments. There was no statistically significant effect of cylinder treatment
(24 hr) at any of the concentrations investigated in any cell line studied.
ND, not determined because 25 mM, 24 hr was toxic to these cell lines.1260 Chemistry & Biology 15, 1258–1267, December 22, 2008 ª2008 Elsevier Ltd All rights reserved
Chemistry & Biology
Cytostatic, Apoptotic, Nongenotoxic Fe CylinderDNA (Figure 3B). We have previously shown that the cylinder
displaces ethidium bromide from naked calf thymus DNA (Han-
non et al., 2001a; Meistermann et al., 2002; Peberdy et al., 2007);
in an analogous experiment it also displaces propidium iodide
(Figure 5A). Therefore, the reduction in propidium fluorescence
in the cellular assays indicates that the cylinder competes with
binding on nuclear chromatin.
Hoechst Displacement Assay
As well as competitively displacing ethidium and propidium from
DNA, the cylinder can displace other DNA binders, such as the
Hoechst dyes, from naked DNA (Peberdy et al., 2007). Hoechst
33258 can also be used to stain DNA in live cells and thus in cel-
lulo displacement may be probed. HL-60 cells were preloaded
with the Hoechst dye (for 20 min) and then treated for 20 min
with the cylinder, before being separated from the media,
washed twice, and resuspended in PBS, and the Hoechst fluo-
rescence was recorded. The Hoechst 33258 fluorescence signal
decreases with increasing amount of cylinder (Figure 5B). This is
consistent with the cylinder entering the cell and displacing
Hoechst 33258 from cellular DNA as it does from naked DNA.
DISCUSSION
The iron(II) cylinders are an exciting new class of agents that act
on DNA in completely different ways from the clinical drug
cisplatin. In particular, the cylinder cannot only bind to the major
groove of DNA (Hannon et al., 2001a; Meistermann et al., 2002;
Moldrheim et al., 2002; Khalid et al., 2006) but it can also fit into
three-way and other Y-shapedDNA junctions (Oleksi et al., 2006;
Cerasino et al., 2007;Malina et al., 2007); Y-shaped junctions are
found endogenously in cells in the form of DNA replication forks.
Importantly, when assessed by the endpoint of inhibition of cell
growth, the potency of iron cylinder [Fe2L3]
4+ (approximately
7 mM) was broadly comparably to that of cisplatin (2.5–5 mM). In
contrast, the IC50 values of the iron cylinder against several tumor
cell lines, determined by an MTT assay of mitochondrial function
in cultures, show an activity ranging from 18 to 57 mMwhich is, on
Figure 2. Inhibition of Cellular Growth by Iron Cylinder
After initial plating at a density of 40,000 cells per dish, cells were cultured in the continuous presence of iron cylinder (0–72 mM) for up to 6 days. Cell number per
35 mm dish was assessed every 24 hr using a hemocytometer as described in Experimental Procedures. The results represent the mean of three individual
experiments repeated in duplicate (n = 3). Error bars plotting SD are omitted for the sake of clarity but were less than ±15% of the mean in all cases.Chemistry & Biology 15, 1258–1267, December 22, 2008 ª2008 Elsevier Ltd All rights reserved 1261
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cisplatin. These results suggest that themolecular-level action of
the iron cylinder is distinct from that of cisplatin and that whereas
both agents are roughly equipotent cytostatic agents, cisplatin is
more efficient at cell killing over the time course investigated.
Interestingly, the MTT IC50 values obtained for the iron cylinder
are more in the range of carboplatin, which is used as an alterna-
tive to cisplatin when there is a clinical need tominimize platinum
drug side effects because of other medical conditions; carbopla-
tin has a lower toxicity and subsequently fewer side effects
(Lippert, 1999; Hannon, 2007b).
On the basis of our findings using a nontumor cell line (MCR5)
as with cisplatin, we are not able to show a greater sensitivity of
tumor cell lines to the cylinder; such potential selectivity would
require further research. Interestingly, activity is seen in all the
Figure 3. Disruption of Parameters Related
to the Cell Cycle by Treatment with Iron
Cylinder
(A) Induction of G1 cell-cycle arrest following treat-
ment with iron cylinder (10 mM, 24 hr) as assessed
by propidium iodide staining of DNA and fluores-
cence activated cell sorting analysis. Plots are
representative and mean values from n = 4 exper-
iments are referred to in the text. Note the accu-
mulation of cells in the G1 phase of the cell cycle
following treatment with iron cylinder [Fe2L3]
4+
(right panel) compared to control (left panel).
(B) Induction of apoptosis as assessed by flow
cytometry and annexin-V staining at 24 and 48 hr
following 25 mMcylinder. Left panels show a repre-
sentative cell cycle for controls (top), 24 hr treat-
ment (middle), and 48 hr (bottom). Right panels
show annexin-V and propidium iodide staining at
24 and 48 hr following 25 mM treatment for control
(top), 24 hr treatment (middle), and 48 hr (bottom).
Cells below the horizontal bar are propidium
iodide-negative (viable) cells. Cells to the right of
the vertical line are annexin positive (apoptotic).
The cells in the top right quadrant are late-stage
apoptotic. The associated table shows the
percentage of events in each stage of the cell
cycle and the percentage of annexin-V-positive
cells. N = 3 experiments ± SD.
tumor cell lines tested in contrast to the
analogous ruthenium(II) compound that
is active in breast but not ovarian lines
(Pascu et al., 2007).
The only other previous example of
anticancer activity by structures with
supramolecular architectures is our
recent report of activity by dinuclear
double-stranded ruthenium complexes
(Hotze et al., 2006). Although one of these
does have higher activity in cell lines
than the cylinders herein, these cylinders
combine a cylinder-like structure with
‘‘vacant’’ coordination sites which can
potentially formdirectmetal-ligandbonds
to the DNA bases, like cisplatin. The
potential anticancer activity of metallo compounds that can
bind only noncovalently to DNA has not been widely studied
and has principally focused on platinum(II) and ruthenium(II) met-
allo intercalators rather than agents that address binding modes
not currently employed by existing clinical drugs (Fisher et al.,
2007;Wheate et al., 2007) (organic intercalators, such as doxoru-
bicin, are currently used in the clinic for cancer treatment). For
example, the simple Tris-chelate [Ru(bpy)3]
2+, a groove binder,
is reported to be inactive, although some related azopyridine-
containing compoundswith potential to (partially) insert between
the bases do display some activity in cell lines (Hotze et al., 2005).
Lincoln and Norde´n (1998) have reported similar IC50 values to
those herein for a dinuclear threading metallo intercalator based
on ruthenium dppz units and whose DNA binding is distinct from
that of simple intercalators. However, the agent is not active in1262 Chemistry & Biology 15, 1258–1267, December 22, 2008 ª2008 Elsevier Ltd All rights reserved
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have very recently described a trinuclear platinum compound
that binds noncovalently (through hydrogen bonds) to the DNA
phosphate backbone in a mode that they describe as ‘‘phos-
phate clamping.’’ Like the cylinders, this synthetic agent has
a mode of binding to DNA that is not used by existing clinical
DNA-targeting drugs. Like the cylinders, it also shows IC50 values
in the micromolar range in cell lines (Harris et al., 2005a, 2005b).
What is particularly exciting is that our studies herein demon-
strate the iron cylinder [Fe2L3]
4+ is not directly genotoxic using
assays of base-pair or frameshift mutagenicity in bacteria and
of DNA strand breaks in human cells. However, at this stage it
is not possibly to completely exclude the possibility that the
iron cylinder may cause mutations through indirect mechanisms
such as inhibition of DNA repair. Many anticancer drugs, specif-
ically cisplatin, covalently bind to DNA, induce oxidative stress,
and cause DNA crosslinking and mutation (Uno and Morita,
1993; Gebel et al., 1997; Cohen and Lippard, 2001). The alkaline
Comet assay was used to indicate whether direct DNA strand
break formation might be involved in the mechanism of action
of the iron cylinder. The Comet assay in intact cells showed
that there was no indication of such DNA damage. These
features (the lack of genotoxicity or mutagenicity) are important
for potential drug design, and the results are in stark contrast to
cisplatin and the other clinical platinum anticancer drugs which
are genotoxic and potent mutagens. The potent genotoxity of
cisplatin can result in the formation of secondary cancers (espe-
cially leukemias) as a result of cancer chemotherapy (Aung et al.,
2002; Escudero et al., 2004; Wierecky et al., 2005), and therefore
the design of metal complexes that have anticancer therapeutic
properties but are not genotoxic or mutagenic would represent
a significant advancement.
Cell-cycle studies in HL-60 cells treated with the iron cylinder
[Fe2L3]
4+ (10 mM for 24 hr) showed a significant G0/G1 arrest
and concomitant lowering of cell numbers in S phase. This
dose did not induce significant apoptosis in either HL-60 or the
adherent cell lines but was similar to that which led to cytostasis
as measured in MTT assays (7 mM). The higher dose of 25 mM
Figure 4. Induction of Apoptosis by Iron
Cylinder [Fe2L3]
4+ as Assessed by the DNA
Diffusion Assay
See Experimental Procedures. The results repre-
sent the mean of three experiments carried out in
duplicate ± SD (n = 3). *, significantly different
from untreated control, p < 0.05 (paired t test).
caused significant apoptosis both in HL-
60 cells and adherent cells. An accumula-
tion of G1 cells was not seen at this dose
but a reduction in S phase remained. It is
reasonable to suggest that these differ-
ences may relate to induced apoptosis
occurring in G0/G1 cells, and further
studies should address this. At 25 mM,
iron cylinder treatment was associated
with apparent binding of cylinder to
cellular DNA, as evidenced by reduced
DNA staining by PI in both cell-cycle and
cytometry-based apoptosis assays. This was not as marked at
10 mM. Thus, the balance between mere G0/G1 arrest and the
additional acquisition of apoptosis appears related to the extent
of DNA binding. During chemotherapy, accumulation of cells in
G0/G1 is as often the result of cell-cycle checkpoint activation
as the result of DNA damage (Wang et al., 2008). In the case of
the iron cylinder, because there is no cleavageof DNA, it is postu-
lated that the noncovalent interaction of the compoundwith DNA
may cause this cell-cycle arrest. It is the first time, to our knowl-
edge, that a noncovalent and nongenotoxic interaction mode of
a supramolecular iron complex with DNA is linked to an arrest
of cells in the cell cycle. Beyond this G0/G1 arrest, we demon-
strate herein, using two separate assays, that the mechanism
of cell toxicity by the iron cylinder is through apoptosis. Although
cellular senescence and cell death by necrosis are also impor-
tant, sensitivity to apoptosis is known to be fundamental for ther-
apeutic responses of malignant cells to chemotherapy including
cisplatin treatment (Reedijk, 1996; Lippert, 1999). Modern drug
design is often based on studies detecting the abilities of investi-
gated complexes to induce apoptosis as the preferred mode of
cell death because it avoids nonselective necrotic mechanisms
that associate with adverse inflammatory responses (Fadeel
and Orrenius, 2005).
Although the precisemolecular basis of the cellular effects and
toxicity of the iron cylinder [Fe2L3]
4+ remains to be fully eluci-
dated, it is immediately clear from the studies herein that its
activity and action are distinct from that of cisplatin and the other
clinical platinum drugs that produce a range of DNA-damaging
events contributing to mutation and cell death (Uno and Morita,
1993; Gebel et al., 1997; Cohen and Lippard, 2001). A mode of
action that contrasts with that of cisplatin opens up the possi-
bility of identifying anticancer treatment for disease with intrinsic
and acquired resistance to agents such as cisplatin. On the basis
of its known noncovalent DNA binding modes, one possible
mechanism is that iron cylinder is able to bind to and stall DNA
replication forks (a three-way junction structure). Whether the
observed cell-cycle arrest ismediated by cell signaling pathways
or more directly through the ability of the agent to coil, andChemistry & Biology 15, 1258–1267, December 22, 2008 ª2008 Elsevier Ltd All rights reserved 1263
Chemistry & Biology
Cytostatic, Apoptotic, Nongenotoxic Fe Cylinderthereby lock away, regions of duplex DNA inhibiting gene
expression is yet to be determined.
SIGNIFICANCE
In the current study, we have shown for the first time, to our
knowledge, that anoncovalent andnongenotoxic interaction
mode of a supramolecular iron complexwithDNA is linked to
an arrest of cells in the G0/G1 phase of the cell cycle and
subsequent death through apoptosis. The design of metal
complexes such as the iron cylinder [Fe2L3]
4+ with potential
anticancer properties in the absence of genotoxicity may
represent a significant step toward therapeutic advance-
ment compared to traditional agents such as cisplatin which
induce cell death through covalent modification to DNA and
genotoxicity. Further research into the mechanism of action
and potential application of iron cylinder and other cylinders
based on other metals, such as the ruthenium(II) cylinder
which also displays activity in cell lines (Pascu et al., 2007),
is currently under way in our laboratories.
EXPERIMENTAL PROCEDURES
Synthesis
Ligand L: 2-pyridine carboxaldehyde (1.4 cm3, 15.1 mmol) and 4,40-methyle-
nedianiline (1.5 g, 7.6 mmol) were stirred in ethanol (25 cm3) at room temper-
ature for 12 hr. The yellow solid that precipitated was collected by vacuum
filtration, recrystallized from ethanol, and dried in vacuo (2.6 g, 84%).
Mass spectrum (= ve FAB): m/z 377 {M + H}.
Found: C, 79.4; H, 5.3; N, 14.7. Calculated for C25H20N4$0.125H2O: C, 79.3;
H, 5.4; N, 14.8%
1HNMR (CDCl3) (250MHz) at 298K: d 8.73 (2H, d, J = 4.0 Hz, H6), 8.65 (2H, s,
Hi), 8.23 (2H, d, J = 7.0 Hz, H3), 7.83 (2H, td, J = 8.3, 1.9, 0.6 Hz, H4), 7.39 (2H,
ddd, J = 7.6, 4.9, 1.2 Hz, H5), 7.29 (8H, m, HPh), 4.07 (2H, s, CH2).
[Fe2L3][PF6]4: ligand L (0.0301 g, 0.08 mmol) and iron(II) chloride (0.0106 g,
0.05 mmol) were heated under reflux in methanol (20 cm3) under dinitrogen
for 2 hr. The resulting purple-colored solution was cooled and treated with
saturated methanolic ammonium hexafluorophosphate. On cooling, a purple
precipitate separated and was isolated by filtration (0.0408 g, 84%).
Mass spectrum (ESI): m/z 310 {Fe2L3}




Found: C, 47.3; H, 3.3; N, 8.7. Calculated for Fe2C75H60N12P4F24$4H2O: C,
47.6; H, 3.6; N, 8.9%
1HNMR (CD3CN) (400MHz) at 233K: d 8.75 (1H, s, Hi), 8.48 (1H, d, J = 7.4 Hz,
H3), 8.34 (1H, t, J = 7.4 Hz, H4), 7.68 (1H, t, J = 6.4 Hz, H5), 7.22 (2H, m, H6,Ph),
6.55 (1H, d, J = 7.8 Hz, HPh), 5.75 (1H, d, J = 6.9 Hz, HPh), 5.17 (1H, d, J = 7.4 Hz,
HPh) 3.98 (1H, s, CH2).
UV/vis (MeCN): 524 (3 = 11,500), 572 (3 = 15,300) nm.
The chloride salt [Fe2L3]Cl4 was prepared by an analogous route.
Mass spectrum (ESI): m/z 310 {Fe2L3}
4+ 100%, 425 {Fe2L3Cl}
3+ 40%.
Found: C, 63.0; H, 4.5; N, 11.6. Calculated for Fe2C75H60N12Cl4$2.5H2O: C,
63.1; H, 4.6; N, 11.8%.
1H NMR (D2O) (300 MHz) at 298K: d 8.89 (1H, s, Hi), 8.44 (1H, d, J = 7.7 Hz,
H3), 8.27 (1H, t, J = 7.7 Hz, H4), 7.58 (1H, t, J = 6.6 Hz, H5), 7.27 (1H, d, J = 5.5
Hz, H6), 7.1 (1H, br, HPh), 6.6 (1H, br, HPh), 5.7 (1H, br, HPh), 5.3 (1H, br, HPh),
3.89 (1H, s, CH2).
UV/vis (H2O): 324 (3 = 32,900), 524 (sh), 574 (3 = 16,900) nm.
Selection of Cell Lines
Wewanted to investigate the biological properties of the iron cylinder [Fe2L3]
4+
in a panel of tumor cell lines in comparison to the effects of cisplatin. HBL100
andT47Dwere selected as representative breast cancer lines that are estrogen
receptor (ER) -positive and -negative, respectively (Freake et al., 1981; Keydar
et al., 1979). Although recently doubt has been cast on the provenance and
veracity of HBL100 as a breast cancer cell line (Lacroix, 2008), the results of
the IC50 that we obtained in this line are included for completeness and allow
comparison with the many other previous studies in that cell line. The SKOV3
cell line is a representative ovarian cancer cell line (Fogh and Orfeo, 1977;
Fogh et al., 1977) and the HL-60 line is a myeloid leukemia line (Gallagher
et al., 1979). All of these lines have abnormal karyotypes and are tumorigenic
in nudemice. As a comparison,we also chose to investigate cylinder properties
in MRC5 cells derived from human fetal lung tissue that has a normal 2n = 46
karyotype (Jacobs, 1966; Jacobs et al., 1970). This is a nonimmortalized line
capable of approximately 42–46 population doublings before senescence.
Cell Culture
All adherent cell lines were routinely cultured in T25 flasks (Nunc) at 37
C in
a humidified, 5% CO2 atmosphere, and maintained as a monolayer in Dulbec-
co’s modified Eagle medium supplemented with 10% fetal bovine serum,
2 mM L-glutamine, 100 U ml1 penicillin, and 0.1 mg ml1 streptomycin. The
suspension cell line HL-60 was cultured in RPMI medium supplemented in
the same manner. Cells were subcultured twice weekly using a standard
trypsin-EDTA protocol with the exception of HL-60 cells, which were split
Figure 5. Iron Cylinder Displaces Fluorescent Probes from Both
Purified and Cellular DNA
(A) Displacement of propidium iodide (1.5 mM) from ct-DNA (6 mM) by iron
cylinder [Fe2L3]
4+. Mixing ratios Pi/cylinder are shown in the caption.
(B) Fluorescence displacement assay for HL-60 cells loaded with 10 mM
Hoechst 33258 and then treated with varying concentrations of cylinder
(concentrations indicated in the figure). lexc = 350 nm.1264 Chemistry & Biology 15, 1258–1267, December 22, 2008 ª2008 Elsevier Ltd All rights reserved
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into 6-well (or 96-well for the MTT assay) culture plates.
MTT Assay and Cellular Growth Assay
TheMTT assay (used to determinemitochondrial reductive function and there-
fore an indicator of cell viability) was utilized to identify the LC50 concentrations
of iron cylinder [Fe2L3]
4+ and cisplatin. Briefly, cells (10,000 per well or 20,000
cells per well for the T47D cell line) were seeded in a 96-well culture plate
(Costar). After a 24 hr period for attachment, cells were incubated in the contin-
uous presence of freshly prepared iron cylinder (0129 mM) or cisplatin (0–
100 mM) for 72 hr. Following treatment, cells were washed with PBS andmedia
were replaced with MTT (0.45 mg ml1) containing growth media and subse-
quently incubated at 37C for 3 hr. Media were aspirated before the addition
of DMSO to solubilize the blue formazan product. Culture plates were gently
rocked for 1 hr before the absorbance was determined at 530 nm against a
DMSO blank. For the cellular proliferation assay, cells (40,000 per well) were
seeded in 6-well culture plates (Costar). After an initial 3 hr period for settle-
ment, cells were incubated in the continuous presence of freshly prepared
iron cylinder (072 mM) or cisplatin (0–5 mM) and cell numbers were calculated
every 24 hr for a 6 day period using an improved Neubauer hemocytometer
(Hawksley Medical and Laboratory Equipment) following trypsinization of cells
where necessary.
Cell-Cycle Analysis
Cells were seeded at 2.5 3 105/ml in 4 ml cultures and were treated with and
without 10 or 25 mM iron cylinder [Fe2L3]
4+. At the appropriate time points,
a 200 ml sample was centrifuged at 500 3 g, the supernatant was removed,
and 500 ml of cell-cycle buffer (10 mg ml1 propidium iodide, 104 M sodium
chloride, 1% Triton X-100 in distilled water) was added. Following vortexing,
samples were stored at 4Cprotected from light andwere analyzed by flow cy-
tometry on a FACS calibur (Becton Dickinson) on 10,000 events, within 48 hr.
Assessment of Apoptosis by Annexin-V/PI Staining
Cells were seeded at 2.5 3 105/ml in 4 ml cultures and were treated with and
without 10 or 25 mM iron cylinder [Fe2L3]
4+. At the appropriate time points,
a 200 ml sample was stained using an annexin-V FITC kit (Becton Dickinson)
according to the manufacturer’s instructions. Binding of annexin-V and uptake
of propidium iodide were analyzed by flow cytometry of 10,000 events on
a Becton Dickinson FACS Calibur utilizing Cell Quest Pro software (Becton
Dickinson). The lower left quadrant shows viable cells, lower right indicates
cells in early stages of apoptosis, upper right is indicative of late apoptosis,
and upper left shows necrotic events.
Propidium Iodide Displacement Assay
Thefluorescence spectra for thePI displacement experimentwere recorded on
a Shimadzu RF-5301 PC fluorescence spectrophotometer (lexc = 535 nm;
range emission = 580–800 nm; resolution = 0.4 nm; speed=medium; excitation
split = 10; emission split = 1.5). Solutions of PI (15 or 1.5 mM), ct-DNA (12, 1.2, or
6 mM), NaCl (50 mM), and sodium cacodylate buffer (1 mM) were prepared,
measured, and tritiated with iron parent cylinder from ratios of PI:iron cylinder
of 200:1 to 4:1, keeping the concentration of PI and ct-DNA constant.
Whole-Cell Hoechst Displacement Assay
The following procedure was that described in Matsuba et al. (2000). HL-60
cells were preincubated with 10 mM Hoechst 33258 in 0.5 ml culture medium
at 37C for 20 min. The iron cylinder was then added (concentrations between
0.1 and100mM) followedbya further 20min incubationat 37C.Cellswere then
collected, washed once with chilled PBS, resuspended in chilled PBS, and the
fluorescence measured. Fluorescence spectra were recorded in a PTIA fluo-
rescence system. The illumination sourcewas aPTI L-201Musinga 75Wxenon
arc lamp. The detection system was a Shimadzu R298 PMT in a PTI model
analog/photon-counting photomultiplier (lexc = 350 nm; range emission =
380–600 nm; speed = 3 nm/s; excitation split = 5; emission split = 1.5).
DNA Diffusion Assay
As a further assessment of apoptosis, the DNA diffusion assay as described
previously (Singh, 2000)was carried out. This assaymeasuresDNA fragmenta-
tion as a result of endonuclease activation, one of the final stages of apoptosis.
In contrast, annexin-V staining (assessing the presence of phosphatidyl serine
in the outer cytoplasmic membrane) is a relatively early temporal marker for
apoptosis. Following treatment with iron cylinder [Fe2L3]
4+ at different concen-
trations, cells (approximately 0.5 3 106) were collected by centrifugation
(8000 rpm, 3min), themedia were removed, and cell pellets were resuspended
in 150 ml of PBS. An aliquot of resuspended cells (15 ml) was placed in a sterile
tube containing low-melting-point agarose (150 ml), and this cell suspension
was transferred to a glass microscope slide (150 ml per slide; BDH) precoated
with 0.5% normal melting-point agarose. Glass coverslips (BDH) were added
and slides were placed on a metal tray over ice for 10 min. Coverslips were
removed and slides were incubated for 1 hr at 4C in lysis buffer (2.5 M NaCl,
0.1 M Na2EDTA, 10 mM Tris base, 1% sodium N-lauryl sarcosinate, 10%
DMSO, 1% Triton X-100). Slides were incubated in alkaline solution (75 mM
NaOH, 0.2% [v/v] DMSO) for 10min. Slideswere then incubated in ethanol con-
taining 1Mammoniumacetate for 15min. Next, slideswere incubated sequen-
tially for 15min with 75% ethanol and neutralization buffer (0.4 M Tris, adjusted
to pH 7.5). Finally, slides were stained with 50 ml of Sybr Gold (Invitrogen; 103
solution). Slides were examined at 3203 magnification using a fluorescence
microscope (Zeiss Axiovert 10) fitted with a 450–490 nm excitation filter and
a barrier of 520 nm. For each slide, 300 nuclei were scored and the number
of apoptotic cells was expressed as a percentage of the total cells scored.
Comet Assay for DNA Strand Breaks
This method was based on that of Singh et al. (1988) as modified in our labora-
tory (Lee et al., 2005). Following the appropriate treatment at different concen-
trations of compound for 24 hr, cells were washed in cold PBS and gently
scraped into fresh PBS (1 ml). Cells were centrifuged (200 3 g, 5 min) and
pellets were resuspended in PBS (150 ml). An aliquot of resuspended cells
(15 ml) was placed in a sterile tube containing low-melting-point agarose
(150 ml), and this cell suspension was transferred to a glass microscope slide
(150 ml per slide; BDH) precoated with 0.5% normal melting-point agarose.
Glass coverslips (BDH) were added and slides were placed on a metal tray
over ice for 10 min. Coverslips were removed and slides were incubated for
1 hr at 4C in lysis buffer (2.5 M NaCl, 0.1 M Na2EDTA, 10 mM Tris base, 1%
sodium N-lauryl sarcosinate, 10% DMSO, 1% Triton X-100). Following lysis,
slides were transferred to a horizontal electrophoresis tank (Pharmacia
Biotech) containing electrophoresis buffer (75 mM NaOH, 1 mM Na2EDTA
[pH 12.8]) and DNA was allowed to unwind for 10 min. DNA was subjected
to electrophoresis (25 V, 0.8 Vcm1, 10 min) and slides were neutralized by
washing (3 3 5 min) with neutralization buffer (0.4 M Tris, adjusted to pH 7.5).
Slides were subsequently stained with 50 ml of Sybr Gold (Invitrogen; 103
solution). Theslideswereexaminedat3203magnificationusingafluorescence
microscope (Zeiss Axiovert 10) fitted with a 515–560 nm excitation filter and
a barrier filter of 590 nm. A USB digital camera (Merlin; Allied Vision Technolo-
gies) received the images, which were analyzed using a personal computer-
based image analysis system, Comet assay IV (Perceptive Instruments).
Images of 100 randomly selected nuclei were analyzed per slide.
Measurement of percent tail DNA (TD%) was chosen to assess the extent of
DNA damage, as this has been shown to suffer much less from interrun varia-
tion than other Comet parameters because it is independent of electrophoresis
voltage and run time (Olive andDurand, 2005). Median values of three separate
experiments were analyzed using ANOVA and post hoc Student’s t test, as
recommended by Duez et al. (2003).
Bacterial Mutagenicity (Ames) Test
Salmonella typhimurium strains TA 98 and TA100 were kindly provided by
Professor B.N. Ames (University of California). Sprague-Dawley rat liver S9
(b-naphthoflavone- and phenobarbital-induced) was obtained from Tebu-Bio
(http://www.tebu-bio.com/). Master cultures of bacteria were prepared ac-
cording to themethod ofMaron and Ames (1983) and the histidine requirement
and genotype were confirmed as recommended in this publication. The assay
was based on the preincubation protocol ofMaron and Ames (1983) and rever-
tant colonies were counted after the plates had been incubated at 37C in the
dark for 24 hr.
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